
Sign up to save your podcasts
Or


Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.
By The Uromigos4.9
5757 ratings
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.

21,838 Listeners

32,110 Listeners

30,680 Listeners

506 Listeners

1,306 Listeners

14 Listeners

58 Listeners

8,674 Listeners

24 Listeners

2 Listeners

59 Listeners

2,031 Listeners

2,049 Listeners

195 Listeners

46 Listeners